| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Thursday, December 01, 2022 3:29:57 AM
Why dilute if you are finalizing a deal?
And what deal pray tell is revive finalizing???
Theyre currently awaiting a response from the fda re an ep change and after that, once approved, the seeking of an eua.
The companys been burning through cash for the past 2 years with the buccy trial and various other psychedelic projects.
Companies use the $$ raised through these means to fund their operations and revive is no different seeing that currently generates no rev$..
Also as stated its not a typical public share offering but rather a private placement transaction thats most likely only open to accredited investors.
And what deal pray tell is revive finalizing???
Theyre currently awaiting a response from the fda re an ep change and after that, once approved, the seeking of an eua.
The companys been burning through cash for the past 2 years with the buccy trial and various other psychedelic projects.
Companies use the $$ raised through these means to fund their operations and revive is no different seeing that currently generates no rev$..
Also as stated its not a typical public share offering but rather a private placement transaction thats most likely only open to accredited investors.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
